VRTX

Vertex Pharmaceuticals Incorporated

Healthcare
428.34 +3.25 +0.76% Market Closed
2026-06-03 • USD

Key Metrics

Market Cap 108.72B
EV —
Shares Out 253.81M
Revenue (ttm) 12.22B
Net Income 4.34B
Beta —
P/E 25.09
Forward P/E —
EPS (ttm) $16.85
P/S 8.91
P/B 5.62
P/FCF —
P/C —
EV/Sales —
EV/EBITDA —
ROA 16.38%
ROE 23.75%
ROIC 18.42%
Gross Margin —
Oper. Margin 38.31%
Profit Margin 35.51%
Debt/Eq 0.10
LT Debt/Eq —
Quick Ratio —
Current Ratio 3.02
Book/sh 76.2
Cash/sh 21.62
Div Yield —
Div TTM —
Payout Ratio —
SMA20 -1.94%
SMA50 -2.04%
SMA200 -1.9%
Volume 1,564,384
Avg Volume 1.35M
Rel Volume —
Perf Week -4.29%
Perf Month 0.94%
Perf Quarter -7.05%
Perf Half Y -5.96%
Perf YTD -5.52%
Perf Year -3.49%
Perf 3Y 28.08%
Perf 5Y 104.04%

Factor Lens

Seasonal Performance

Financial Trends

Revenue & Net Income

Earnings Per Share

Margins

Cash Flow

Company Overview

Vertex Pharmaceuticals is a global biotechnology company focused on discovering, developing, and commercializing innovative medicines by combining transformative advances in human disease understanding and therapeutic science. The company has approved medicines for cystic fibrosis (CF), sickle cell disease (SCD), transfusion-dependent beta thalassemia (TDT), and acute pain. For CF, Vertex markets five CFTR modulator therapies: ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor), TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor), SYMDEKO/SYMKEVI (tezacaftor/ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor). For SCD and TDT, Vertex offers CASGEVY (exagamglogene autotemcel), a CRISPR/Cas9-based gene-editing therapy. For acute pain, the company launched JOURNAVX (suzetrigine), a first-in-class NaV1.8 pain signal inhibitor. The company's mid- and late-stage clinical pipeline includes five pivotal programs: povetacicept for IgA nephropathy and primary membranous nephropathy, inaxaplin for APOL1-mediated kidney disease, suzetrigine for diabetic peripheral neuropathy, and zimislecel for type 1 diabetes. The company also has earlier-stage programs in autosomal dominant polycystic kidney disease, myotonic dystrophy type 1, and generalized myasthenia gravis. Vertex commercializes products primarily through specialty pharmacies and specialty distributors globally, with direct marketing to healthcare professionals. The company is dedicated to ensuring broad access to therapies through reimbursement arrangements and patient support programs.

Name
Vertex Pharmaceuticals Incorporated
Industry
Drug Manufacturers - General
CEO
Reshma Kewalramani · Chief Executive Officer and President
Employees
—
IPO Date
2020-04-24
Phone
(617) 341-6100
Address
50 Northern Avenue, Boston, MA 02210
Website
—

Key Executives

Name Title FY Pay
Nia Tatsis Executive Vice President —
Amit Sachdev Executive Vice President, Chief Commercial Officer —
Carmen Bozic Chief Medical Officer —
Jeffrey M. Leiden Executive Chairman —
Reshma Kewalramani Chief Executive Officer and President —

Latest News